The therapeutic potential of 5-HT1A receptors: a patent review

被引:32
作者
Lacivita, Enza [1 ]
Di Pilato, Pantaleo [1 ]
De Giorgio, Paola [1 ]
Colabufo, Nicola A. [1 ]
Berardi, Francesco [1 ]
Perrone, Roberto [1 ]
Leopoldo, Marcello [1 ]
机构
[1] Univ Bari A Moro, Dipartimento Farmacochim, I-70125 Bari, Italy
关键词
anxiety; central nervous system; depression; G-protein-coupled receptors; medicinal chemistry; neurogenesis; pain; Parkinson's disease; schizophrenia; serotonin 5-HT1A receptor; structure-activity relationships; PARKINSONS-DISEASE; NEURONS; HIPPOCAMPAL; SEROTONIN; 5-HYDROXYTRYPTAMINE; BUSPIRONE; AGONISTS; ANTAGONIST; LIGANDS; NEUROTRANSMISSION;
D O I
10.1517/13543776.2012.703654
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Introduction: The 5-HT1A receptors are implicated in mood disorders (anxiety, depression), in cognition, and in modulation of pain. Nearly 30 years of research in this field, there is still interest in developing new chemical entities capable of 5-HT1A receptor activation or blockade. Areas covered: This review article will highlight and review the research advances published in the patent literature between January 2007 and December 2011, giving emphasis to the medicinal chemist's standpoint. Literature search methodology included search in Scifinder and PubMed Databases and browsing clinicaltrials. gov website. Expert opinion: Almost no new therapeutic applications have been proposed for molecules targeting the 5-HT1A receptor, during the years covered by the present review. The discovery that stimulation of 5-HT1A receptor can promote neurogenesis will likely renew the interest for selective 5-HT1A receptor agonists as therapeutics to replace neural populations damaged by disease or injury.
引用
收藏
页码:887 / 902
页数:16
相关论文
共 92 条
[1]  
Anderson J.H., 2010, US Pat., Patent No. [0331341 A1, 0331341]
[2]   F15599, a highly selective post-synaptic 5-HT1A receptor agonist: in-vivo profile in behavioural models of antidepressant and serotonergic activity [J].
Assie, Marie-Bernadette ;
Bardin, Laurent ;
Auclair, Agnes L. ;
Carilla-Durand, Elisabeth ;
Depoortere, Ronan ;
Koek, Wouter ;
Kleven, Mark S. ;
Colpaert, Francis ;
Vacher, Bernard ;
Newman-Tancredi, Adrian .
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2010, 13 (10) :1285-1298
[3]  
Astra Zeneca AB, 2009, Patent No. [US0093461, 0093461]
[4]  
Asubio Pharma Co. Ltd, 2009, Patent No. [WO09069828, 09069828]
[5]  
Atir Holding SA, 2010, Patent No. [WO10137018, 10137018]
[6]   Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder [J].
Bang-Andersen, Benny ;
Ruhland, Thomas ;
Jorgensen, Morten ;
Smith, Garrick ;
Frederiksen, Kristen ;
Jensen, Klaus Gjervig ;
Zhong, Huailing ;
Nielsen, Soren Moller ;
Hogg, Sandra ;
Mork, Arne ;
Stensbol, Tine Bryan .
JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (09) :3206-3221
[7]   MODIFICATION OF 5-HT NEURON PROPERTIES BY SUSTAINED ADMINISTRATION OF THE 5-HT1A AGONIST GEPIRONE - ELECTROPHYSIOLOGICAL STUDIES IN THE RAT-BRAIN [J].
BLIER, P ;
DEMONTIGNY, C .
SYNAPSE, 1987, 1 (05) :470-480
[8]   Is there a role for 5-HT1A agonists in the treatment of depression? [J].
Blier, P ;
Ward, NM .
BIOLOGICAL PSYCHIATRY, 2003, 53 (03) :193-203
[9]   A SYNAPTIC MODEL OF MEMORY - LONG-TERM POTENTIATION IN THE HIPPOCAMPUS [J].
BLISS, TVP ;
COLLINGRIDGE, GL .
NATURE, 1993, 361 (6407) :31-39
[10]   NEUROTRANSMISSION - THE LINK INTEGRATING ALZHEIMER RESEARCH [J].
BOWEN, DM ;
FRANCIS, PT ;
CHESSELL, IP ;
WEBSTER, MT .
TRENDS IN NEUROSCIENCES, 1994, 17 (04) :149-150